Jenburkt Pharmaceuticals MD, chairman, board of directors and AGM
NSE: JENBURPHBSE: 524731Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹871.40.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹384 Cr1,871st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 6 Aug 2026
- 11.7
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.95 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 5 May 2026
- 2.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.38%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- 17.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.95 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- 19.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 5 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,34093.5% delivered
Jenburkt Pharmaceuticals board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorASHISH UTTAM BHUTARelated to the promoter
- Company Secretary and Compliance OfficerASHISH R. SHAH
6 directors4 independent2 executive
- ASHISH UTTAM BHUTA · Chairperson and managing directorExecutive · joined Jun 2007 · reappointed Apr 2026 · 1 listed board · 1 committee seat
- DILIP HARKISHANDAS BHUTAExecutive · joined Jul 2013 · reappointed Apr 2022 · 1 listed board · 1 committee seat
- HINA RAVINDRA MEHTAIndependent · joined Sep 2020 · reappointed Mar 2025 · 72 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- SUMIT AJAYBHAI THAKKARIndependent · joined Jul 2023 · 38 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- KRISHNAN SUBHARAMANIndependent · joined May 2024 · 28 months as independent · 1 listed board · 1 as independent · 1 committee seat
- PANKAJ ARUN DANTWALAIndependent · joined May 2024 · 28 months as independent · 1 listed board · 1 as independent · 2 committee seats
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 6 Aug 20266 of 6 present4 independent · 92 days in between
- 5 May 20266 of 6 present4 independent
Audit Committee
Chair HINA RAVINDRA MEHTA
KRISHNAN SUBHARAMAN, PANKAJ ARUN DANTWALA, DILIP HARKISHANDAS BHUTA
- 6 Aug 20264 of 4 present3 independent · 92 days in between
- 5 May 20264 of 4 present3 independent
Nomination and remuneration committee
Chair KRISHNAN SUBHARAMAN
HINA RAVINDRA MEHTA, SUMIT AJAYBHAI THAKKAR
- 6 Aug 20263 of 3 present3 independent · 92 days in between
- 5 May 20263 of 3 present3 independent
Stakeholders Relationship Committee
Chair SUMIT AJAYBHAI THAKKAR
PANKAJ ARUN DANTWALA, ASHISH UTTAM BHUTA
- 6 Aug 20263 of 3 present2 independent · 92 days in between
- 5 May 20263 of 3 present2 independent
Corporate Social Responsibility Committee
Chair KRISHNAN SUBHARAMAN
PANKAJ ARUN DANTWALA, DILIP HARKISHANDAS BHUTA, ASHISH UTTAM BHUTA
- 6 Aug 20264 of 4 present2 independent · 92 days in between
- 5 May 20264 of 4 present2 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- D.R.Mehta & AssociatesPeer-review certificate valid to Mar 2028
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Jenburkt Pharmaceuticals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Jenburkt Pharmaceuticals dividend history
Annual general meeting, 4 Sep 2026
7,332 shareholders on the register on 28 Aug 2026; present: 4 promoters and 47 others; votes counted by Nilesh Shah / Nilesh Shah & Associates.The company's voting result (opens in a new tab)
- To consider and adopt the audited financial statements of the Company for the financial year ended on 31st March, 2026, together with the Board of Directors' and Auditors' report thereon.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 43.64% · promoters 93.14% · institutions 0.00% · other public 0.42%
- To declare a dividend of ? 20.70 (207%) per equity share of ? 10/- each, for the financial year ended on 31st March, 2026.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 43.64% · promoters 93.14% · institutions 0.00% · other public 0.42%
- To appoint a director, in place of Shri Dilip H. Bhuta (DIN- 03157252), who retires by rotation and being eligible, offers himself for re-appointment as a Director, liable to retire by rotation.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 43.63% · promoters 93.14% · institutions 0.00% · other public 0.39%
- To re-appoint Shri Dilip H. Bhuta (DIN-03157252), as the Whole Time Director and Chief Financial Officer (CFO) of the Company.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 43.63% · promoters 93.14% · institutions 0.00% · other public 0.39%
- To ratify the remuneration payable to Cost Auditor of the Company for the financial year 2026-27.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 43.64% · promoters 93.14% · institutions 0.00% · other public 0.42%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.